Specialty Vehicle Engineering has announced a new, more-extreme addition to the Yenko performance heritage with the debut of ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback